S. Petroni

发表

BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.

A. Paradiso, S. Tommasi, F. Schittulli, 2005, Mutation research.

Colorectal Clinical Experimental Oncology Laboratory and 2

A. Paradiso, P. Johnston, C. Allegra, 2022 .

Benefit from anthracyclines in relation to biological profiles in early breast cancer

E. Scarpi, D. Amadori, P. Sismondi, 2013, Breast Cancer Research and Treatment.

Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.

G. Serio, D. Galetta, S. Petroni, 2016, Translational lung cancer research.

Correlation between ERICA and DCC assay in hormone receptor assessment of human breast cancer.

A. Paradiso, S. Tommasi, S. Petroni, 1988, Oncology.

nm23 expression in malignant ascitic effusions of serous ovarian adenocarcinoma.

S. Petroni, C. Campobasso, A. Leone, 2001, International journal of oncology.

P16(INK4a) protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: diagnostic and clinical considerations.

S. Petroni, G. Trojano, O. Popescu, 2014, Cancer biomarkers : section A of Disease markers.

Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?

S. Petroni, E. Mattioli, C. Quero, 2012, Archives of pathology & laboratory medicine.

FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics

S. Petroni, A. Mangia, F. Giotta, 2016, Oncology letters.

BRCA1 expression and molecular alterations in familial breast cancer.

A. Paradiso, S. Tommasi, F. Menolascina, 2009, Histology and histopathology.

BRCA 1 expression and molecular alterations in familial breast cancer

A. Paradiso, S. Tommasi, F. Menolascina, 2008 .

RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease.

A. Paradiso, F. Schittulli, S. Petroni, 2008, International journal of molecular medicine.

Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers.

S. Tommasi, A. Paradiso, F. Schittulli, 2008, Cancer genetics and cytogenetics.

TROP‐2 expression in papillary thyroid cancer: a preliminary cyto‐histological study

S. Petroni, O. Popescu, G. Simone, 2015, Cytopathology : official journal of the British Society for Clinical Cytology.

Timing of breast cancer surgery within the menstrual cycle: tumor proliferative activity, receptor status and short-term clinical outcome.

A. Paradiso, F. Schittulli, S. Petroni, 1998, Journal of experimental & clinical cancer research : CR.

P47 BRCA1, ER-alpha expression and molecular BRCA1 alterations in familial and sporadic breast cancer

A. Paradiso, S. Tommasi, F. Menolascina, 2007 .

[Ki67 as histochemical marker of cellular proliferative activity in breast cancer].

G. Rella, A. Paradiso, S. Petroni, 1988, Pathologica.

© 2000 Cancer Research Campaign

A. Paradiso, P. Johnston, A. Eggermont, 2022 .

Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

A. Paradiso, S. Petroni, M. Lena, 2000, British Journal of Cancer.

Predictive role of thymidylate synthase (TS) and p53 primary tumor expression in advanced colorectal cancer

A. Paradiso, P. Johnston, S. Petroni, 1997 .

nm23 expression in human breast cancer: correlation with cell proliferation (S-phase) as observed with a double-labeling immunocytochemical-autoradiographic technique.

A. Paradiso, S. Petroni, M. de Lena, 1998, International journal of oncology.